Melanoma: targeting signaling pathways and RaLP

Bibliography

• Liu V, Mihm MC. Pathology of malignant melanoma. Surg Clin North Am 2003;83(1):31-60
   PubMed Web of Science ®Google Scholar
• Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006;355(1):51-65
   PubMed Web of Science ®Google Scholar
• Scolyer RA, Murali R, McCarthy SW, Thompson JF. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol 2008;25(2):100-11
   PubMedGoogle Scholar
• Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005;115(4):813-24
   PubMed Web of Science ®Google Scholar
• Gogas HJ, Kirkwood JM, Sondak V. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109(3):455-64
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol 2007;34(6):532-45
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
   PubMed Web of Science ®Google Scholar
• Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22(20):3138-51
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24(29):4738-45
   PubMed Web of Science ®Google Scholar
• Grover R, Wilson GD. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur J Surg Oncol 1996;22(4):347-9
   PubMedGoogle Scholar
• Pilla L, Valenti R, Marrari A, et al. Vaccination: role in metastatic melanoma. Expert Rev Anticancer Ther 2006;6(8):1305-18
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Agarwala SS. Interleukin-2 for the treatment of melanoma. Curr opin investig drugs 2005;6(12):1234-9
   PubMedGoogle Scholar
• Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 2006;19(1):19-25
   PubMed Web of Science ®Google Scholar
• Bennett DC. How to make a melanoma: what do we know of the primary clonal events? Pigment cell melanoma res 2008;21(1):27-38
   PubMed Web of Science ®Google Scholar
• Hayward NK. Genetics of melanoma predisposition. Oncogene 2003;22(20):3053-62
   PubMed Web of Science ®Google Scholar
• Crowson AN, Magro C, Miller AJ, Mihm MC. The molecular basis of melanomagenesis and the metastatic phenotype. Semin Oncol 2007;34(6):476-90
   PubMedGoogle Scholar
• Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006;25(38):5220-7
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Argenziano G, Zalaudek I, Peris K. High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Rev Anticancer Ther 2006;6(5):657-70
   PubMed Web of Science ®Google Scholar
• Sekulic A, Haluska P Jr, Miller AJ, et al. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 2008;83(7):825-46
   PubMed Web of Science ®Google Scholar
• Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6(3):184-92
   PubMed Web of Science ®Google Scholar
• Mc Kay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007;26(22):3113-21
   PubMedGoogle Scholar
• Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003;22(20):3087-91
   PubMed Web of Science ®Google Scholar
• Haluska F, Pemberton T, Ibrahim N, Kalinsky K. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol 2007;34(6):546-54
   PubMed Web of Science ®Google Scholar
• Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004;5(10):816-26
   PubMed Web of Science ®Google Scholar
• Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol 2007;25(12):1606-20
   PubMed Web of Science ®Google Scholar
• Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445(7130):851-7
   PubMed Web of Science ®Google Scholar
• Fagiani E, Giardina G, Luzi L, et al. RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas. Cancer Res 2007;67(7):3064-73
   PubMedGoogle Scholar
• Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006;24(1):21-44
   PubMed Web of Science ®Google Scholar
• Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci 2004;117(Pt 20):4619-28
   PubMed Web of Science ®Google Scholar
• Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr opin Oncol 2008;20(2):183-9
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26(22):3279-90
   PubMed Web of Science ®Google Scholar
• Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 2007;19(2):117-23
   PubMed Web of Science ®Google Scholar
• Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 2006;38(3):200-11
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116(6):855-67
   PubMed Web of Science ®Google Scholar
• Gray-Schopfer V, Da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 2005;24(1):165-83
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004;64(7):2338-42
   PubMed Web of Science ®Google Scholar
• Cohen C, Zavala-Pompa A, Sequeira JH, et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 2002;8(12):3728-33
   PubMed Web of Science ®Google Scholar
• Grichnik JM. Kit and melanocyte migration. J Invest Dermatol 2006;126(5):945-7
   PubMedGoogle Scholar
• Roskoski R. Signaling by Kit protein-tyrosine kinase–the stem cell factor receptor. Biochem Biophys Res Commun 2005;337(1):1-13
   PubMed Web of Science ®Google Scholar
• Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63(4):756-9
   PubMed Web of Science ®Google Scholar
• Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 2003;115:145-67
   PubMedGoogle Scholar
• Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001;61(9):3819-25
   PubMed Web of Science ®Google Scholar
• Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999;274(19):13085-90
   PubMed Web of Science ®Google Scholar
• Li G, Kalabis J, Xu X, et al. Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene 2003;22(44):6891-9
   PubMedGoogle Scholar
• Govindarajan B, Sligh JE, Vincent BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007;117(3):719-29
   PubMed Web of Science ®Google Scholar
• Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant V600EB-Raf cooperate to promote early melanoma development. Cancer Res 2008;68(9):3429-39
   PubMed Web of Science ®Google Scholar
• Davies MA, Stemke-Hale K, Tellez C, et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008;99(8):1265-8
   PubMed Web of Science ®Google Scholar
• Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev 2005;24(2):273-85
   PubMed Web of Science ®Google Scholar
• Wu H, Goel V, Haluska F. PTEN signaling pathways in melanoma. Oncogene 2003;22(20):3113-22
   PubMed Web of Science ®Google Scholar
• Gu J, Tamura M, Pankov R, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 1999;146(2):389-403
   PubMed Web of Science ®Google Scholar
• Stahl JM, Cheung M, Sharma A, et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003;63(11):2881-90
   PubMed Web of Science ®Google Scholar
• Van Der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res 2001;305(3):285-98
   PubMed Web of Science ®Google Scholar
• Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 2007;1775(1):163-80
   PubMed Web of Science ®Google Scholar
• Schwartz MA, Horwitz AR. Integrating adhesion, protrusion, and contraction during cell migration. Cell 2006;125(7):1223-5
   PubMed Web of Science ®Google Scholar
• Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285(5430):1028-32
   PubMed Web of Science ®Google Scholar
• Eliceiri BP, Cheresh DA. Adhesion events in angiogenesis. Curr Opin Cell Biol 2001;13(5):563-8
   PubMed Web of Science ®Google Scholar
• Howe AK, Aplin AE, Juliano RL. Anchorage-dependent ERK signaling–mechanisms and consequences. Curr Opin Genet Dev 2002;12(1):30-5
   PubMed Web of Science ®Google Scholar
• Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev 2005;24(2):195-222
   PubMed Web of Science ®Google Scholar
• Barberis L, Wary KK, Fiucci G, et al. Distinct roles of the adaptor protein Shc and focal adhesion kinase in integrin signaling to ERK. J Biol Chem 2000;275(47):36532-40
   PubMedGoogle Scholar
• Luzi L, Confalonieri S, Di Fiore PP, Pelicci PG. Evolution of Shc functions from nematode to human. Curr Opin Genet Dev 2000;10(6):668-74
   PubMed Web of Science ®Google Scholar
• Jones N, Hardy WR, Friese MB, et al. Analysis of a Shc family adaptor protein, ShcD/Shc4, that associates with muscle-specific kinase. Mol Cell Biol 2007;27(13):4759-73
   PubMed Web of Science ®Google Scholar
• Migliaccio E, Mele S, Salcini AE, et al. Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J 1997;16(4):706-16
   PubMed Web of Science ®Google Scholar
• Pelicci G, Troglio F, Bodini A, et al. The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 2002;22(20):7351-63
   PubMedGoogle Scholar
• Kojima T, Yoshikawa Y, Takada S, et al. Genomic organization of the Shc-related phosphotyrosine adapters and characterization of the full-length Sck/ShcB: specific association of p68-Sck/ShcB with pp135. Biochem Biophys Res Commun 2001;284(4):1039-47
   PubMedGoogle Scholar
• Cattaneo E, Pelicci PG. Emerging roles for SH2/PTB-containing Shc adaptor proteins in the developing mammalian brain. Trends Neurosci 1998;21(11):476-81
   PubMedGoogle Scholar
• Nakamura T, Muraoka S, Sanokawa R, Mori N. N-Shc and Sck, two neuronally expressed Shc adapter homologs. Their differential regional expression in the brain and roles in neurotrophin and Src signaling. J Biol Chem 1998;273(12):6960-7
   PubMed Web of Science ®Google Scholar
• Sakai R, Henderson JT, O'Bryan JP, et al. The mammalian ShcB and ShcC phosphotyrosine docking proteins function in the maturation of sensory and sympathetic neurons. Neuron 2000;28(3):819-33
   PubMed Web of Science ®Google Scholar
• Lai KM, Pawson T. The ShcA phosphotyrosine docking protein sensitizes cardiovascular signaling in the mouse embryo. Genes Dev 2000;14(9):1132-45
   PubMed Web of Science ®Google Scholar
• Migliaccio E, Giorgio M, Mele S, et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999;402(6759):309-13
   PubMed Web of Science ®Google Scholar
• Ravichandran KS. Signaling via Shc family adapter proteins. Oncogene 2001;20(44):6322-30
   PubMed Web of Science ®Google Scholar
• Trinei M, Giorgio M, Cicalese A, et al. A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. Oncogene 2002;21(24):3872-8
   PubMed Web of Science ®Google Scholar
• Pelicci G, Lanfrancone L, Grignani F, et al. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 1992;70(1):93-104
   PubMed Web of Science ®Google Scholar
• Troglio F, Echart C, Gobbi A, et al. The Rai (Shc C) adaptor protein regulates the neuronal stress response and protects against cerebral ischemia. Proc Natl Acad Sci USA 2004;101(43):15476-81
   PubMedGoogle Scholar
• Ursini-Siegel J, Muller WJ. The ShcA adaptor protein is a critical regulator of breast cancer progression. Cell Cycle 2008;7(13):1936-43
   PubMed Web of Science ®Google Scholar
• Grossman SR, Lyle S, Resnick MB, et al. p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer. Clin Cancer Res 2007;13(19):5798-804
   PubMed Web of Science ®Google Scholar
• Terui E, Matsunaga T, Yoshida H, et al. Shc family expression in neuroblastoma: high expression of shcC is associated with a poor prognosis in advanced neuroblastoma. Clin Cancer Res 2005;11(9):3280-7
   PubMedGoogle Scholar
• Schlessinger J, Lemmon MA. SH2 and PTB domains in tyrosine kinase signaling. Sci STKE 2003;2003(191):RE12
   PubMedGoogle Scholar
• Sebolt-Leopold J, English JM. Mechanisms of drug inhibition of signalling molecules. Nature 2006;441(7092):457-62
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Haluska F. Novel inhibitors in the treatment of metastatic melanoma. Expert Rev Anticancer Ther 2007;7(5):715-24
   PubMed Web of Science ®Google Scholar
• Meier F, Busch S, Lasithiotakis KG, et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 2007;156(6):1204-13
   PubMed Web of Science ®Google Scholar
• Smalley KS, Haass NK, Brafford PA, et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5(5):1136-44
   PubMed Web of Science ®Google Scholar
• Flaherty KT. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 2006;12(7 Pt 2):s2366-70
   PubMedGoogle Scholar
• Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109(3):455-64
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006;95(5):581-6
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23(23):5281-93
   PubMed Web of Science ®Google Scholar
• Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106(9):2005-11
   PubMed Web of Science ®Google Scholar
• Jaissle GB, Ulmer A, Henke-Fahle S, et al. Suppression of melanoma-associated neoangiogenesis by bevacizumab. Arch Dermatol 2008;144(4):525-7
   PubMedGoogle Scholar
• Bedogni B, Welford SM, Kwan AC, et al. Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther 2006;5(12):3071-7
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Smith D, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat rev Drug discov 2005;4(12):988-1004
   PubMed Web of Science ®Google Scholar
• Ihle NT, Williams R, Chow S, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004;3(7):763-72
   PubMed Web of Science ®Google Scholar
• Ernst DS, Eisenhauer E, Wainman N, et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest new drugs 2005;23(6):569-75
   PubMed Web of Science ®Google Scholar
• Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a Phase II trial of the California Cancer Consortium. Cancer 2005;104(5):1045-8
   PubMed Web of Science ®Google Scholar
• Mousa SA. Cell adhesion molecules: potential therapeutic & diagnostic implications. Mol Biotechnol 2008;38(1):33-40
   PubMed Web of Science ®Google Scholar
• Eskens FA, Dumez H, Hoekstra R, et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours. Eur J Cancer 2003;39(7):917-26
   PubMed Web of Science ®Google Scholar
• Posey JA, Khazaeli MB, Del Grosso A, et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti αvβ3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001;16(2):125-32
   PubMed Web of Science ®Google Scholar
• Hoek KS, Eichhoff OM, Schlegel NC, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008;68(3):650-6
   PubMed Web of Science ®Google Scholar
• Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406(6795):536-40
   PubMed Web of Science ®Google Scholar
• Winnepenninckx V, Van Den Oord JJ. Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors. Expert Rev Anticancer Ther 2007;7(11):1611-31
   PubMed Web of Science ®Google Scholar
• Molnár V, Tamási V, Bakos B, et al. Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas. Semin Cancer Biol 2008;18(2):111-22
   PubMed Web of Science ®Google Scholar
• Ursini-Siegel J, Hardy WR, Zuo D, et al. ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J 2008;27(6):910-20
   PubMedGoogle Scholar